Brief: Corxel And Lenz Therapeutics Announce Positive Topline Data From China Phase 3 Presbyopia Trial Of Lnz100

LENZ Therapeutics

28/10/2024 01:01

Oct 27 (Reuters) - Lenz Therapeutics Inc  LENZ.O :
    * CORXEL AND LENZ THERAPEUTICS ANNOUNCE POSITIVE TOPLINE
DATA FROM
CHINA PHASE 3 PRESBYOPIA TRIAL OF LNZ100
    * LENZ THERAPEUTICS INC - PRIMARY ENDPOINT MET WITH 74%
IMPROVEMENT AT 3 HOURS POST TREATMENT

Source text:  ID:nGNX91sC2C 
Further company coverage:  LENZ.O 

 ((Reuters.Briefs@thomsonreuters.com;))